Page 37 - Demo

Panitumumab and chemoradiation for inoperable pancreatic cancer352Table 2. continued)AE, n (%)Cohort 1.0 mg/kg (n =3)Cohort 1.5 mg/kg (n =6)Cohort 2.0 mg/kg (n =5)Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4Hemorrhage/bleedingEpistaxis%u2014 %u2014 %u2014 %u2014 1 (20) %u2014Gastrointestinal %u2014 %u2014 %u2014 %u2014 1 (20) %u2014Metabolic/laboratoryElevated transaminases%u2014 %u2014 1 (17) %u2014 %u2014 %u2014Hypomagnesemia %u2014 %u2014 %u2014 %u2014 1 (20) %u2014InfectionCellulitis1 (33) %u2014 %u2014 %u2014 %u2014 %u2014Urinary tract infection %u2014 %u2014 1 (17) %u2014 %u2014 %u2014Response, PFS, and OS One patient in the 1 mg/kg cohort was diagnosed with LAPC based on cytology, but when he developed metastatic disease, histology revealed a pancreatic neuroendocrine tumor. Therefore, this patient was evaluated for toxicity, but not for tumor response, PFS, and OS. In Table 3, the median PFS and OS of the patients treated in this study are shown. The median PFS of all cohorts together is 8.9 months (range, 3.5%u201323), including 1 patient who had stable disease under study treatment according to protocol after 10.9 months of follow-up. The median PFS in the MTD cohort is 11.8 months (range, 3.7%u201323). Two of the 13 patients evaluable for response were still alive at the time of evaluation; both were treated in the MTD cohort. The median OS in all cohorts together is 12.3 months (range, 4.0%u201330.1 months), including the 2 patients who were alive at the last evaluation (respectively 10.9 and 20.1 months from start until last evaluation). The median OS in the MTD cohort is 17.0 months (range, 10.9%u201325.8), including 2 patients who were alive at the last evaluation. Three patients achieved a partial response (23%), whereas all other patients had stable disease as best response. Median duration of gemcitabine monotherapy after chemoradiation is 3.9 months for all patients and 4.3 months for the patients treated in the MTD cohort, including the last patient still under study treatment after 10.9 months follow-up. CA19.9 response was reached by 8 of the 13 (61.5%) for response evaluable patients, 5 of them were treated in the MTD cohort. These 8 patients had stable disease when reaching CA19.9 response and a median PFS and OS of respectively 9.9 and 13.0 months.